Paradigm: Investigate New Drug (IND) update
Paradigm Biopharmaceuticals Ltd (ASX:PAR) is very close to IND approval, however, there remains uncertainty around when the company can expect to be given the green light. Based on the timeline of events, we are confident that, providing the company provides the FDA’s required information within the month, we can expect to know the outcome by October 3. Whilst any delay is not ideal, we believe Paradigm remains on course to unlock PPS as a blockbuster drug. Read our full update, including Q&A, here.
Paradigm CEO, Paul Rennie, and Paradigm management have provided a thorough update which we believe encapsulates the company’s current state of affairs. Watch the video presentation here.